title: CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC.
abstract: B-chronic lymphocytic leukaemia (B-CLL) is a heterogeneous disease characterized by an accumulation of B lymphocytes expressing CD5. To date, the biological significance of this molecule in B-CLL B cells remains to be elucidated. In this study, we have analysed the functional consequences of the binding of an anti-CD5 antibody on B-CLL B cells. To this purpose, we have measured the percentage of viability of B-CLL B cells in the presence or in the absence of anti-CD5 antibodies and also examined some of the biochemical events downstream the CD5-signalling. We demonstrate that anti-CD5 induces phosphorylation of protein tyrosine kinases and protein kinase C (PKC), while no activation of Akt/PKB and MAPKs is detected. This signalling cascade results in viability in a group of patients in which we observe an increase of Mcl-1 levels, whereas the levels of bcl-2, bcl-x(L) and XIAP do not change. We also report that this pathway leads to IL-10 production, an immunoregulatory cytokine that might act as an autocrine growth factor for leukaemic B cells. Inhibition of PKC prevents the induction of Mcl-1 and IL-10, suggesting that the activation of PKC plays an important role in the CD5-mediated survival signals in B cells from a subset of B-CLL patients.
authors.affiliation: Fundacion LAIR, Madrid, Spain.
authors.forename: Gema
authors.initials: G
authors.lastname: Perez-Chacon
authors.forename: Juan A
authors.initials: JA
authors.lastname: Vargas
authors.forename: Julia
authors.initials: J
authors.lastname: Jorda
authors.forename: Marta
authors.initials: M
authors.lastname: Morado
authors.forename: Silvia
authors.initials: S
authors.lastname: Rosado
authors.forename: Trinidad
authors.initials: T
authors.lastname: Martin-Donaire
authors.forename: Ignacio
authors.initials: I
authors.lastname: Losada-Fernandez
authors.forename: Nerea
authors.initials: N
authors.lastname: Rebolleda
authors.forename: Paloma
authors.initials: P
authors.lastname: Perez-Aciego
mesh_terms: D017209:Apoptosis / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D018956:CD5 Antigens / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D002470:Cell Survival; D002478:Cells, Cultured; D006801:Humans; D016753:Interleukin-10 / Q000096:biosynthesis; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000276:immunology*; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009363:Neoplasm Proteins / Q000096:biosynthesis; D011493:Protein Kinase C / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D015398:Signal Transduction / Q000276:immunology*
chemical_list: D018956:CD5 Antigens; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016753:Interleukin-10; D011493:Protein Kinase C